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1. Past 
When searching the history of antiphospholipid antibodies one must meet cornerstone in 
Graham Hughes’s descriptions of antiphospholipid syndrome in his “Prosser-White 
Oration” to the British Society of Dermatology in 1983 (Hughes GRV; 1984). The main points 
of his lecture can be found in different publications (Hughes GRV; 1984, Hughes GRV; 1999, 
Khamastha MA; 2000) and they are still truthful although they have been expressed almost 
thirty years ago. He finished his own work (Hughes GRV 1980; Hughes GRV; 1983) and 
crowned also another authors’ important publication and observations. Some of these 
should be mentioned like the presence of false positive Wasserman reactions and also 
presence of circulating coagulants in patients with systemic lupus erythematosus (Laurel 
BB, Nilsson IM; 1957), the association of such circulating anticoagulants with thromboses 
(Bowie EJW et al 1983) and term “lupus anticoagulant” designation (Feinstein DI, Rapaport 
SI; 1972). The publication concerning association of these autoantibodies with foetal losses 
(Boey ML, et al; 1983) or the article which was directed to laboratory diagnostics (Harris EN, 
et al; 1983) arose almost at the same time as the Hughes’s syndrome description.  
The next important milestone emerged in 1990 when three independent working groups 
described the role of2-glycoprotein I as a target antigen in antiphospholipid antibodies’ 
action (Galli M, et al; 1990, Matsura E, et al; 1990, McNeil HP, et al; 1990). This discovery 
substantially changed point of view of many of the researchers and also clinical practisers in 
the topic and it led to research of 2-glycoprotein I structure, function and confirmation of 
significance of its antibodies presence during the next years. 
As the important fact in our knowledge in antiphospholipid antibodies presence has to be 
stressed that laboratory investigation of lupus anticoagulants bodies has been under a 
control almost from the earliest time of their “standard” guidelines formulation (Exner T, et 
al; 1991, Barna LK, Triplett DA; 1991). The same situation is true in other antiphospholipid 
antibodies’ detection and the experts have been searching continuously the solution to this 
problem until nowadays. Descriptions of the clinical manifestation of antiphospholipid 
antibodies’ presence accompanied by antiphospholipid syndrome’s definition were created 
in patients with systemic lupus erythematosus in the late eightieths and early ninetieths 
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(Alacrón-Segóvia D, et al; 1989a, Alacrón-Segóvia D, et al. 1992) and the definition and 
description of primary and also catastrophic antiphospholipid syndrome (Asherson RA, et 
al. 1989, Alacrón-Segóvia D, et al; 1989b) arose at the almost same time. This effort had led to 
so call Sapporo criteria of antiphospholipid syndrome which were generally accepted and 
widely used for many years (Wilson WA, et al; 1998).  
2. Presence 
Let’s start “presence” twenty years after the antiphospholipid syndrome’s description with 
two really important publications by Monica Galli (Galli M, et al; 2003a, Galli M, et al; 
2003b) which summarised association of different type of antiphospholipid antibodies and 
their clinical significance in patients based on meta-analyses. The international consensus 
statement for definition of catastrophic antiphospolipid was published at the same year 
(Asherson RA, et al; 2003) and it was based on agreement by international workshop 
(during the international congress on antiphospholipid antibodies at Taormina, Italy 2002). 
The information from these articles has retained its importance until now. 
The antiphopholipid syndrome’s definition changed after discussion which started in 
international congress on antiphospholipid antibodies at Syndey 2004 (Miyakis S, at al. 
2006). This consensus statement also determined non-criteria manifestations of 
antiphospholipid antibodies like thrombocytopenia, nephropathy and cardiac valve disease 
or livedo reticularis. 
The important debate concerning serological criteria occurred at the pages of Journal of 
Thrombosis and Haemostasis in years 2007-2009 (Swadzba J, et al; 2007, Ruffatti A, et al; 
2008, Galli M, et al; 2008, Pengo V; 2008, Tripodi A; 2008, Swadzba J et at; 2009, Ruffatti A, et 
al; 2009). The main finding from this debate seemed to be recommendation that the “cut off” 
in anticardiolipin antibodies’ testing should be defined separately for thrombotic risk 
assessment and for pregnancy complication (Rufatti A, et al. 2008) and confirmation of the 
fact that the highest risk of clinical manifestation of antiphospholipid syndrome depends on 
the “triple positivity” of antiphospholipid antibodies, which means presence of lupus 
anticoagulant, significant positivity of anticardiolipin antibodies IgG and anti- 2-
glycoprotein I antibodies. Recommendation for lupus anticoagulant detection was also 
updated recently (Pengo V, et al; 2009, Tripodi A; 2009). The whole laboratory diagnostic 
process has been summarised in important publications (Gianacopulous B, et al; 2009, Pengo 
V, et al. 2010, Roubey RAS; 2010) including clinical meaning and critical analysis of different 
results.  
An attempt to summarise briefly current knowledge in pathophysiology of 
antiphospholipid antibodies’ action is a real “mission impossible”. The same is true for the 
attempt to only list important researchers on the field. The compact overview bring 
Giannakopoulos (Giannakopoulos B, et al; 2007) or Meroni (Meroni PL; 2008). The role of 
prothrombotic and proinflammatory phenotype of endothelial cells, monocytes and 
platelets via direct action of antiphosholipid antibodies has been summarised by Pierangelli 
(Pierangelli SS, et al;2006). The connection between antiphospholipid antibodies, 
complement and foetal losses has been described for the first time by Holers (Holers VM, et 
al; 2002) and this research led to next association with tissue factor’s role (Redecha P, et al; 
2007). The most recent knowledge in pathophysiology of antiphospholipid antibodies was 
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widely discussed at the 13th international congress on anthiphospholipid antibodies, which 
was held in April 2010 at Galveston, Texas, USA. The role of innate immunity was described 
by Rauch (Rauch J, et al; 2010). The role of tissue factor was summarised by Boles and 
Mackman (Boles J, Mackman N; 2010). The pathophysiology of 2-glycoprotein I was 
discussed by Matsuura (Matsuura E, et al. 2010), the role of the receptor LRP8 by de Groot 
(de Groot PG, et al. 2010) and involvement of protein C pathway by Urbanus (Urbanus RT, 
de Last B; 2010). The annexin A5-mediated mechanism in pregnancy losses and thrombosis 
was clarified by Rand (Rand JH, et al. 2010). These are the most important but definitely not 
all publications concerning antiphospholipid antibodies pathophysiology at this congress.  
3. Perspectives 
The great progression of our knowledge in antiphospholipid antibodies, their action and 
clinical manifestation is attended by arising of new questions and problems to be solved. 
Some of these have been opened by Lockshin many years ago (Lockshin MD; 2000) and not 
all of them have been answered until now. Many different experts of various specialisations 
like investigators, animal models experts, laboratory diagnosis specialists, clinicians and 
epidemiologists assign a lot of important tasks. Some of them should be mentioned. 
3.1 Other autoantibodies 
Evidence is increasing that a lot of other autoantibodies could be found in patients with 
antiphospholipid syndrome and/or with another clinical manifestation of antiphospholipid 
antibodies (Shoenfeld Y, et al; 2008). What is their role and how they could be involved in 
antiphospholipd syndrome diagnose? 
3.2 Other diagnostic tools 
Some new diagnostic procedures, which seem to bring new information for 
antiphospholipid antibodies’ positive patients, have been described recently. The first of all 
is evaluation of circulating antibodies against domain I of 2-glycoprotein I (de Laat B, et al 
2005, de Laat B, et al. 2009). The positive finding correlates with thrombotic and obstetric 
history in IgG type of these autoantibodies. Next example is ELISA detection of IgG 
phosphatidylserine-dependent antiprothrobmin antibodies which seem to be associated 
with antiphospholipid syndrome manifestation and also with lupus anticoagulant presence 
(Atsumi T, Koike T; 2010). The open question is also the meaning of finding of the presence 
of autoantibodies directed to phospholipid itself (Tebo AE, et al. 2008). These examples 
belong to the most important discoveries which should be verified in daily clinical practice. 
3.3 Therapy of antiphospholipid syndrome and antiphospholipid antibodies presence 
The standard approach of the management of the antiphospholipid syndrome’s 
manifestation has been described and accepted widely (Derksen RHWM, de Groot PG; 2010, 
Cervera R, et al; 2010). Other thing is primary prophylaxis of thromboembolic event in 
patient with asymptomatic course. Some recommendation but also controversy information 
in this field exist (Erkan D, et al; 2007, Metjian A, Lim W; 2009), but these patients’ 
management has been considered as the open question until now. The new approaches with 
new directions which need to prove their action are under investigation. Some of new 
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antithrombotic drugs have proved their effectiveness in patient with thromboembolic 
disease when they were compared with vitamin K antagonists. The direct oral thrombin 
inhibitor dabigatran has a predictable anticoagulant effect and its safety profile is similar to 
that of warfarin (Schulman S, et al; 2009). Also rivaroxaban, an oral factor Xa inhibitor offers 
a simple, single-drug approach to the treatment of venous thrombosis that may improve the 
benefit-to-risk profile of anticoagulation (Bauersachs R, et al as the Einstein Investigators; 
2010). These drugs are fixed-dose oral agents which do not appear to require routine 
laboratory monitoring and they may have a potential role in the management of patients in 
certain clinical manifestation of antiphospholipid syndrome. Among patients with acute 
venous thromboembolism approximately 10% have antiphospholipid antibodies and 
therefore it is likely that those patients were included in the study population in the 
dabigatran and rivaroxaban trials (Cohen H, Machin SJ; 2010). The potential advantages of 
these drugs in antiphospholipid antibodies positive patients have to be mentioned. The first 
of all is well known complicated laboratory monitoring in vitamin K dependent oral 
anticoagulant in the cases of lupus anticoagulants presence (Tripody A, et al; 2001). The 
second reasons which could favourite the new antithrombotic drugs is the fact that warfarin 
failures more frequently in secondary prevention in venous thromboembolisms in 
antiphospholipid antibodies than in other indications (Ames PRJ, et al; 2005, Wittkowsky 
AK, et al; 2006, Kearon C, et al; 2008). 
Another approaches which could be involved in antiphospholipid antibodies positive 
persons management in future is potential immunomodulatory effect of some drugs. There 
are involved for example tissue factor up-regulation’s inhibition, nuclear factor B up-
regulation’s inhibition, p38 mitogen activated protein kinase up-regulation’s inhibition, role 
of hydroxychloroquine, statins, anti-C5 monoclonal antibodies action or those against the 
lymphocytes bearing CD 20 receptor (rituximab) and other therapeutic modalities which 
role is supported only by animal models or only by episodic experiences in human 
(Pierangeli SS, Erkan D; 2010). 
Vitamin D inhibits proinflamatory processes by suppressing the enhanced activity of 
immune cells that take part in autoimmune reactions. Shoenfeld Y, et al. intend to determine 
basal levels of vitamin D in patient with antiphospholipid syndrome and to identify those 
who require vitamin D supplementation, and to establish the therapeutic dose (Arnson Y, et 
al; 2007, Rotar Z, et al; 2009).  
3.4 Other point of interest for the future 
Future direction for antiphospholid syndrome research should concern some more opened 
questions. In aetiology of antiphospholipid antibodies the problems of infections, tumours, 
drugs and genetic predisposition could be involved. The meaning and managing of clinical 
manifestations associated with antiphopsholipid antibodies presence in which 
thromboembolic events are not suppose to be involved in clinical course also remains to be 
established (Shoenfeld Y, et al; 2008).  
The next directions of the investigation at the field should be directed in paediatric patients. 
It includes newborns born to antiphospholipid antibodies positive mothers and their long-
term clinical and immunological follow-up, paediatric antiphospholipid syndrome registry 
and clinical and laboratory differences between paediatric and adult patient with 
antipphospholipid syndrome (Rotar Z, et al; 2009, Avcin T, Silverman ED; 2007).  
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The really open field for next investigation seems to be mechanisms of antiphospholipid 
antibodies generation and action. The questions concerning why they occur or not, which 
pathways could be involved in their generation and next action, what are predisposing risk 
factors for their formation and clinical manifestation and many other still waiting for their 
solution. 
4. Persons 
It has been mentioned before and it will be mentioned once again later in this book that the 
problem of antiphospholipid antibodies and their effect really need interdisciplinary 
approaches. The leading persons in discovery of current knowledge of antiphospholipid 
antibodies and their action, clinical manifestation, detection and management are listed at 
the references of this chapter bellow, they belong to contributors of the next chapters of this 
book or they are mentioned in the references in these chapters. But, it should be stressed out, 
that persons themselves, theirs’ contributions and publications, imagine and experiences 
and their willingness to share their knowledge are necessary requirements which could lead 
to important progress at the topic. 
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